CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report 2018 fourth quarter and full year financial results after market close on Thursday, March 14, 2019. Ra Medical management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 866-789-3291 | ||
| International | 409-937-8946 | |||
| Passcode | 1696453 | |||
| Live Webcast: | ||||
| The webcast will be archived for 30 days. | ||||
| Replay: | U.S. | 855-859-2056 | ||
| International | 404-537-3406 | |||
| Passcode | 1696453 | |||
| The replay will be available for 48 hours | ||||
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017, the DABRA laser system and disposable DABRA catheter received FDA 510(k) clearance in the U.S. for the intended use of ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Independent in vivo and in vitro research studies have demonstrated that 308 nanometer excimer laser light, which is the same wavelength used in DABRA and Pharos, increases T-cell apoptosis, or cell death, which may produce an immunosuppressive effect. Ra Medical manufactures its DABRA and Pharos excimer lasers and catheters in its approximately 32,000-square-foot facility located in Carlsbad, California. Ra Medical’s vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in its controlled environments.